Previous Close | 0.2500 |
Open | 0.2400 |
Bid | 0.1500 |
Ask | 0.3500 |
Strike | 2.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.2400 - 0.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 19 |
Explore key financial outcomes and strategic milestones from Codexis Inc's first quarter of 2024, reflecting robust growth and promising developments.
Despite a Net Loss, Codexis Demonstrates Strong Revenue Growth and Strategic Milestones
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today an